Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer.
The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following the discontinuation of cisplatin. Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium less than 1.4 mg/l), including 3 patients with serum magnesium values less than 1.0 mequiv/l. The median cisplatin-free interval for these 9 patients was 19 months (range 6-40 months). We conclude that persistent, and possibly permanent, hypomagnesemia is common following cisplatin chemotherapy.
Markmann
M
M
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Rothman
R
R
Reichman
B
B
Hakes
T
T
Lewis
J L
JL
Rubin
S
S
Jones
W
W
Almadrones
L
L
Hoskins
W
W
D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000097:blood*; D010051:Ovarian Neoplasms / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D013997:Time Factors
D008274:Magnesium; D002945:Cisplatin